Robotic versus video-assisted lobectomy/segmentectomy for lung cancer: a meta-analysis
H Liang, W Liang, L Zhao, D Chen, J Zhang… - Annals of …, 2018 - journals.lww.com
Objective: To compare the safety/efficacy of the robotic-assisted lobectomy/segmentectomy (RAL/S)
with the video-assisted lobectomy/segmentectomy (VAL/S) for radical lung cancer …
with the video-assisted lobectomy/segmentectomy (VAL/S) for radical lung cancer …
[HTML][HTML] Artificial intelligence for stepwise diagnosis and monitoring of COVID-19
H Liang, Y Guo, X Chen, KL Ang, Y He, N Jiang… - European …, 2022 - Springer
Background Main challenges for COVID-19 include the lack of a rapid diagnostic test, a
suitable tool to monitor and predict a patient’s clinical course and an efficient way for data …
suitable tool to monitor and predict a patient’s clinical course and an efficient way for data …
[HTML][HTML] The alteration of T790M between 19 del and L858R in NSCLC in the course of EGFR-TKIs therapy: a literature-based pooled analysis
H Liang, Z Pan, W Wang, C Guo, D Chen… - Journal of thoracic …, 2018 - ncbi.nlm.nih.gov
… All data were recorded independently by two researchers (HR Liang and DF Chen). Any
conflict was resolved by the third researcher (WH Liang). For the selected studies, information …
conflict was resolved by the third researcher (WH Liang). For the selected studies, information …
[HTML][HTML] The impact of postoperative EGFR-TKIs treatment on residual GGO lesions after resection for lung cancer
…, S Xiong, H Liang, Z Liu, W Zeng, W Liang… - … and Targeted Therapy, 2021 - nature.com
In recent years, the incidence of multifocal lung cancer is increasing, called multiple primary
lung cancer (MPLC). Synchronous MPLC (sMPLC) is defined by multiple malignant lesions …
lung cancer (MPLC). Synchronous MPLC (sMPLC) is defined by multiple malignant lesions …
[HTML][HTML] Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China
W Liang, W Guan, R Chen, W Wang, J Li, K Xu… - The lancet …, 2020 - thelancet.com
China and the rest of the world are experiencing an outbreak of a novel betacoronavirus
known as severe acute respiratory syndrome corona virus 2 (SARS-CoV-2). 1 By Feb 12, 2020, …
known as severe acute respiratory syndrome corona virus 2 (SARS-CoV-2). 1 By Feb 12, 2020, …
Development and validation of a clinical risk score to predict the occurrence of critical illness in hospitalized patients with COVID-19
W Liang, H Liang, L Ou, B Chen, A Chen… - JAMA internal …, 2020 - jamanetwork.com
Importance Early identification of patients with novel coronavirus disease 2019 (COVID-19)
who may develop critical illness is of great importance and may aid in delivering proper …
who may develop critical illness is of great importance and may aid in delivering proper …
[HTML][HTML] Early triage of critically ill COVID-19 patients using deep learning
W Liang, J Yao, A Chen, Q Lv, M Zanin, J Liu… - Nature …, 2020 - nature.com
The sudden deterioration of patients with novel coronavirus disease 2019 (COVID-19) into
critical illness is of major concern. It is imperative to identify these patients early. We show that …
critical illness is of major concern. It is imperative to identify these patients early. We show that …
Neoadjuvant camrelizumab plus chemotherapy for resectable, locally advanced esophageal squamous cell carcinoma (NIC‐ESCC2019): a multicenter, phase 2 study
…, W Lv, W Cai, W Liang, H Liang… - … Journal of Cancer, 2022 - Wiley Online Library
Optimal treatment for resectable esophageal squamous cell carcinoma (ESCC) is
controversial, especially in the context of potential benefit of combining PD‐1 blockade with …
controversial, especially in the context of potential benefit of combining PD‐1 blockade with …
Evaluation of clinical and safety outcomes of neoadjuvant immunotherapy combined with chemotherapy for patients with resectable esophageal cancer: a systematic …
…, C Li, Y Wen, Y Jiang, H Liang, J He, W Liang… - JAMA network …, 2022 - jamanetwork.com
Importance A considerable number of clinical trials of neoadjuvant immunotherapy for patients
with resectable esophageal cancer are emerging. However, systematic evaluations of …
with resectable esophageal cancer are emerging. However, systematic evaluations of …
Efficacy and safety of first line treatments for patients with advanced epidermal growth factor receptor mutated, non-small cell lung cancer: systematic review and …
…, Z Xie, H Liang, W Wang, Z Guo, S Zhao, W Liang… - Bmj, 2019 - bmj.com
Objective To compare the efficacy and safety of first line treatments for patients with advanced
epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer (NSCLC). …
epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer (NSCLC). …
